卜先乐,姚秀卿,王延江

• 1:第三军医大学大坪医院神经内科

摘要(Abstract)：

<正>2013年阿尔茨海默病协会国际会议(Alzheimer's Association International Conference 2013,AAIC 2013)于7月13~18日在美国波士顿召开。此次会议对过去一年中在阿尔茨海默病(Alzheimer's disease,AD)研究方面取得的进展进行交流,本文对在发病机制、危险因素、诊断和防治等方面取得的重要进展进行介绍。1发布AD防治的新路线图阿尔茨海默病协会(Alzheimer's Association)和美国疾病控制中心(CDC)在本次会议上联合发布了AD防治的新路线图,呼吁社会各界把认知

关键词(KeyWords)：

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 卜先乐,姚秀卿,王延江

参考文献(References)：

• [1]Snyder HM,Bain LJ,Egge R,et al.Alzheimer's disease publicprivate partnerships:A landscape of the global nonprofit community[C].Alzheimers Dement,2013,9(4):466-471.
• [2]Diamond M.Tau as a prion:Mechanisms and implications[C].Alzheimers Dement,2013,9:673
• [3]Frain L,Swanson D,Betensky R,et al.A reduced risk of Alzheimer's disease is associated with the majority of cancers in a national cohort of veterans[C].Alzheimer's&dementia:the journal of the Alzheimer's Association,2013,9:617.
• [4]Dufouil C,Pereira E,Chêne G,et al.Older age at retirement is associated with decreased risk of dementia:Analysis of a health care insurance database of self-employed workers[C].Alzheimer's&dementia:the journal of the Alzheimer's Association,2013,9:342-343.
• [5]Jessen F.A conceptual framework of subjective cognitive decline(SCD)in preclinical Alzheimer's disease(AD)[C],Alzheimer's&dementia:the journal of the Alzheimer's Association,2013,9:824.
• [6]Jack C,Knopman D,Jagust W,et al.Update on hypothetical model of Alzheimer's disease biomarkers[C].Alzheimer's&dementia:the journal of the Alzheimer's Association,2013,9:521-522.
• [7]Bertens D,Scheltens P,Visser PJ.Temporal evolution of biomarkers and cognitive markers from preclinical to clinical Alzheimer's disease:An Alzheimer's Disease Neuroimaging Initiative(ADNI)study[C].Alzheimer's&dementia:the journal of the Alzheimer's Association,2013,9:523.
• [8]Vos S,Xiong C,Grant E,et al.Using cerebrospinal fluid markers to identify stages of National Institute on Aging and Alzheimer’s Association proposed criteria for preclinical Alzheimer's disease and its prognosis[C].Alzheimers Dement,2013,9:682.
• [9]Klunk W,Cohen A,Snitz B,et al.Conversion to MCI and amyloid-positivity in normal controls[C].Alzheimers Dement,2013,9:150.
• [10]Villemagne V,Burnham S,Bourgeat P,et al.The natural history of the dynamics of beta-amyloid deposition,neurodegeneration and cognitive decline in sporadic Alzheimer's disease[C].Alzheimer's&dementia:the journal of the Alzheimer's Association,2013,9:523-524.
• [11]Ran C,Zhang XL,Moore A.Curcumin analogues attenuate copper-induced crosslinking of beta-amyloid[C].Alzheimer's&dementia:the journal of the Alzheimer's Association,2013,9:503-504.
• [12]Mintun M,Schwarz A,Joshi A,et al.Exploratory analyses of regional human brain distribution of the PET tau tracer F18-labeled T807(AV-1541)in subjects with normal cognitive function or cognitive impairment thought to be due to Alzheimer's disease[C].Alzheimers Dement,2013,9:842.
• [13]Kolb H,Attardo G,Mintun M,et al.First case report:Image to autopsy correlation for tau imaging with[18F]-T808(AV-680)[C].Alzheimers Dement,2013,9:844-845.
• [14]Harada R,Okamura N,Furumoto S,et al.Binding characterization of novel PET tracer[18F]THK-5117 in the brains of people with Alzheimer's disease[C].Alzheimers Dement,2013,9:276-277.
• [15]Shimada H,Higuchi M,Shinotoh H,et al.In vivo visualization of tau pathology in Alzheimer's disease patients by[11C]PBB3-PET[C].Alzheimers Dement,2013,9:845.
• [16]Ross J,Sharma SK,Chatterjee A,et al.Sustained cognitive benefit in patients with mild cognitive impairment(MCI)upon prolonged treatment with CHF5074[C].Alzheimers Dement,2013,9:530.
• [17]Forman M,Kleijn H-J,Dockendorf M,et al.The novel BACE inhibitor MK-8931 dramatically lowers CSF beta-amyloid in patients with mild-to-moderate Alzheimer's disease[C].Alzheimers Dement,2013,9:139.
• [18]Whitmer R,Quesenberry C,Allison J,et al.Anti-hyperglycemic therapy and risk of dementia:A new user cohort study[C].Alzheimers Dement,2013,9:136.
• [19]Roses A,Welsh-Bohmer K,Burns D,et al.A pharmacogeneticssupported clinical trial to delay onset of mild cognitive impairment due to Alzheimer's disease[C].Alzheimers Dement,2013,9:727.
• [20]Relkin N.Results of the GAP 160701 study:A phase 3 clinical trial of intravenous immunoglobulin for mild-to-moderate Alzheimer's disease[C].Alzheimers Dement,2013,9:530.
• [21]Counts S,Perez S,Mufson E.IVIG reduces tau pathology and increases neuroplastic gene expression in the 3xTg mouse model of Alzheimer's disease[C].Alzheimers Dement,2013,9:356.
• [22]Lahiri D,Ray B.Effect of IVIg in preserving human primary neurons and protecting them against oxidative stress[C].Alzheimers Dement,2013,9:800.
• [23]Evans CF,Davtyan H,Petrushina I,et al.Epitope-based DNA vaccine for Alzheimer's disease:Translational study in macaques[C].Alzheimers Dement,2013.
• [24]Khachaturian AS,Meranus DH,Kukull WA,et al.Big data,aging,and dementia:Pathways for international harmonization on data sharing[C].Alzheimer's&dementia:the journal of the Alzheimer's Association,2013,9:61-62.